DSIP (Delta Sleep-Inducing Peptide)

DSIP (Delta Sleep-Inducing Peptide) (Inj)

DSIP (delta sleep-inducing peptide) is a naturally occurring nonapeptide originally isolated from cerebral venous blood and studied for potential roles in sleep regulation, stress physiology, and neuroendocrine signaling. DSIP research is mixed; some studies suggest effects on sleep architecture and stress responses, while others show variable or minimal effects depending on model and administration route.

Dosing Protocols

— 5 mg Vial —

Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
Typical daily range: 100–300 mcg once daily (gradual titration); advanced up to 500 mcg.
Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.

Schedule: Daily subcutaneous injections for 4–8 weeks (extend to 12 weeks if desired).
Cycle Length: 4–8 weeks; optional extension to 12 weeks with periodic breaks.
Goal: Support healthy sleep architecture and stress modulation over time.

Frequency: Inject once daily subcutaneously, typically in the evening before bedtime.

Phase	Dose	Syringe (U-100)
Week 1	100 mcg	6 units (0.06 mL)
Week 2	150 mcg	9 units (0.09 mL)
Week 3	200 mcg	12 units (0.12 mL)
Weeks 4–8	250–300 mcg	15–18 units (0.15–0.18 mL)
Weeks 6–8+	400–500 mcg	24–30 units (0.24–0.30 mL)

— 10 mg Vial —

Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
Typical daily range: 100–300 mcg once daily in the evening (gradual titration).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.

Schedule: Daily subcutaneous injections in the evening for 8–12 weeks.
Cycle Length: 8–12 weeks; consider a break after the cycle.
Goal: Support improved sleep quality, enhanced delta-wave (slow-wave) sleep, and stress modulation over time.

Frequency: Inject once daily subcutaneously in the evening, approximately 30–60 minutes before bedtime.

Phase	Dose	Syringe (U-100)
Week 1	100 mcg	3 units (0.03 mL)
Week 2	150 mcg	5 units (0.05 mL)
Week 3	200 mcg	6 units (0.06 mL)
Weeks 4–8	250–300 mcg	8–9 units (0.08–0.09 mL)

Benefits

• May influence sleep onset and sleep architecture in some experimental settings.
• Potential modulation of stress-response pathways (HPA-axis related findings in some models).
• Studied for possible antioxidant and neuroprotective effects under stress conditions (preclinical).
• Investigated for potential effects on pain perception and withdrawal-related symptoms in limited research contexts.
• May modulate endocrine signaling in experimental models.

Mechanism of Action

The precise mechanism remains incompletely defined. DSIP has been reported to interact with multiple neurochemical systems and may influence hypothalamic regulation of endocrine outputs. Observed effects vary by species, timing, dose, and route. In research contexts, DSIP is sometimes framed as a stress-protective peptide with downstream impacts on sleep regulation rather than a single receptor-specific agonist.

Side Effects

Potential adverse effects reported in literature and/or anecdotally include:

• Daytime drowsiness or fatigue.
• Vivid dreams or altered sleep patterns.
• Headache.
• Transient nausea.
• Injection-site irritation.

Side Effect Management

• Dose earlier in the evening and avoid driving if residual sedation occurs.
• Reduce dose/frequency if next-day grogginess occurs.
• Use sterile technique and rotate injection sites.
• Avoid combining with sedatives/alcohol unless explicitly designed.

Contraindications

• Pregnancy or breastfeeding.
• Concurrent sedative/hypnotic medications without oversight (additive CNS depression).
• History of severe depression or suicidality (sleep agents can worsen mood in some individuals).
• Seizure disorders (limited data; use caution).

Research Citations

PubMed-linked citations for verification. Many studies are preclinical (animal/in-vitro).

1. Delta sleep-inducing peptide (DSIP): an update on structure, function and possible clinical applications. Neuropeptides. 2014. PMID: 24937372 (doi: 10.1016/j.npep.2014.05.001)
2. Delta sleep-inducing peptide: occurrence, structure and biological effects. Peptides. 2006. PMID: 16930770 (doi: 10.1016/j.peptides.2006.07.011)
3. DSIP and stress-protective effects in experimental models (review). Peptides. PubMed

---